MarketPulse

peanut allergy immunotherapy

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Dbv Technologies

DBV Technologies' Peanut Allergy Patch Shows Strong Phase 3 Data Ahead of FDA Submission

DBV Technologies' peanut allergy patch met Phase 3 goals with 46.6% responder rate versus 14.8% placebo, supporting planned 2026 FDA submission.
DBVTFDA approvalBLA submission
GlobeNewswire Inc.GlobeNewswire Inc.··Dbv Technologies

DBV Technologies' Peanut Allergy Patch Shows Strong Phase 3 Data Ahead of FDA Submission

DBV Technologies announced strong Phase 3 data for VIASKIN® Peanut patch, with 82.8% of treated children showing improved tolerance. FDA submission planned for H1 2026.
DBVTFDA approvalclinical trial results